Twitter Facebook LinkedIn YouTube

Sirona Biochem has signed an agreement with Contract Manufacturing Organization WuXi AppTec in Shanghai, for the small-scale production of TFC-1326, a powerful active against the aging effects on skin.

Video Platform Video Management Video Solutions Video Player

Sirona Biochem (TSXV:SBM) (FSE:ZSB) (OTCPink:SRBCF) has signed an agreement with Contract Manufacturing Organization WuXi AppTec in Shanghai, for the small-scale production of TFC-1326, a powerful active against the aging effects on skin. Years of ground-breaking research by Sirona’s team of scientists at TFChem has shown in preclinical studies that TFC-1326 has the potential to reverse the effects of aging on skin, including the potential to eliminate fine wrinkles.

Additional Information:

Company: Sirona Biochem Corp
Website: https://www.sironabiochem.com/
Stock Symbol: TSXV:SBM
Date Published: Jun 22, 2022
Transcript: Available

Video Transcript:

Sirona Biochem (TSXV:SBM) (FSE:ZSB) (OTCPink:SRBCF) has signed an agreement with Contract Manufacturing Organization WuXi AppTec in Shanghai, for the small-scale production of TFC-1326, a powerful active against the aging effects on skin.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver ground-breaking treatments to patients.

Years of ground-breaking research by Sirona’s team of scientists at TFChem has shown in preclinical studies that TFC-1326 has the potential to reverse the effects of aging on skin, including the potential to eliminate fine wrinkles.

The company’s state-of-the-art TFChem Laboratory, is located in Val de Reuil, France, France’s Cosmetic Valley,
where the world’s leading cosmetic companies conduct their research and development.

TFChem has received multiple French national scientific awards and European Union and French government grants.

The company is in advanced discussions with a leading clinical trial provider designing the planned clinical trial.

Other necessary steps, including formulation and safety work, are being organized and as soon as they are completed and the clinical study starts, the company plans to provide further information.

Company scientists are not aware of any existing compounds that have the potential to reverse the effects of the aging process on skin and to truly restore its structure and youthful appearance.

The anti-aging and anti-wrinkle markets are estimated to be $271 Billion USD globally by 2024.

Management believes this technology could also be potentially applied to other cosmetic categories such as hair care, makeup and suncare.

Dr Howard Verrico, CEO, stated: “There are many anti-aging and anti-wrinkle products available on the market currently. But to truly reverse the damage to the skin integrity that occurs naturally with aging is an area of unmet need. Our goal is to demonstrate clinically the potential of TFC-1326 to restore the integrity of the skin and return a more youthful appearance. The treatment of fine wrinkles is also a goal. BOTOX® is the most effective on dynamic wrinkles while static wrinkles typically are managed by fillers. TFC-1326 has the potential to replace or supplement dermal filler injections to treat these static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space. Like our recent success, licensing TFC-1067 and the corresponding compound family globally, we see this as another opportunity to showcase the tremendous potential of our platform technology. And, of course, we are pursuing another lucrative licensing agreement for TFC-1326.”

Sirona Biochem, a cosmetic ingredient and drug discovery company with a proprietary platform technology, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety.

The company’s world-class team is comprised of award-winning scientists who have worked for Fortune 500 companies such and Sanofi, GSK and Bayer.

New compounds are patented for maximum revenue potential and licensed to leading cosmetics and pharma companies around the world in return for licensing fees, milestone payments and ongoing royalty payments.

Sirona's two most advanced programs are its cosmetic skin lightener and a diabetes drug, with other products in its pipeline.

The shares are trading at $0.27.

For more information, please visit the company’s website at www.SironaBiochem.com

Investor Relations is handled by Jonathan Williams, of Momentum PR, who can be reached at 450-332-6939 or by email at jwilliams@momentumpr.com.